

BME – GROWTH

Palacio de la Bolsa
Plaza de la Lealtad, 1
28014 Madrid

Alicante, 30th June 2023

COMMUNICATION- OTHER RELEVANT INFORMATION- FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 227 of the Law 6/2023 17th March, Spanish Securities Market and Investment Services, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "FacePhi" or "the Company", interchangeably).

During the Ordinary General Meeting of Shareholders of FACEPHI BIOMETRÍA, S.A. (hereinafter, "FACEPHI" or the "Company"), held on 30th June 2023, at first call, with the attendance of a total of 19 shareholders, present or represented, and representing a total of 29,09 of the share capital, all the resolutions submitted to vote in accordance with the notice of the General Meeting published at the time were approved. The resolutions adopted are as follows:

FIRST: Examination and approval of the annual accounts (comprising the balance sheet, profit and loss account, statement of changes in equity, cash flow statement and notes), together with the management report for the year ended 31 December 2022.

The annual accounts of the Company for the year ended 31 December 2021 (comprising the balance sheet, the profit and loss account, the statement of changes in equity, the cash flow statement and the notes to the financial statements) together with the management report, as prepared by the Board of Directors of the Company on 31 March 2023, are unanimously approved.

SECOND: Examination and approval of the consolidated annual accounts (comprising the consolidated balance sheet, profit and loss account, statement of changes in equity, cash flow statement and notes to the financial statements, all of which are consolidated), together with the consolidated management report for the year ended 31 December 2022.

The consolidated annual accounts of the Group for the year ended 31 December 2022 (comprising the consolidated balance sheet, the consolidated income statement, the consolidated statement of changes in equity, the consolidated cash flow statement and the consolidated notes to the financial statements) together with the consolidated management report, as prepared by the Board of Directors of the Company on 31 March 2023, are unanimously approved.

THIRD: Examination and approval, as the case may be, of the proposal for the application of the Company's results corresponding to financial year 2022.

The board's proposal to allocate the result for the year, amounting to 2,052,553 euros, to "Negative results from previous years" in the amount of 1,841,328 euros, to "Legal reserve" in the amount of 30,909 euros and 180,316 euros to "Voluntary reserves" was unanimously approved.

FOURTH: Examination and approval, as the case may be, of the management carried out by the Board of Directors of the Company for the financial year 2022.

The management of the Board of Directors during the financial year ended 31 December 2022 was unanimously approved.

FIFTH: Approval, as the case may be, of the remuneration to be received by the executive officers of the Company, as well as by the members of the Board of Directors during the 2023 financial year.

The remuneration to be received by the Executive Director and by the members of the Board of Directors during the financial year 2023 is It is approved unanimously.

SIXTH: Renewal, or appointment as the case may be, of the auditor of the accounts of the Company and its consolidable group, to audit the individual and consolidated annual accounts for the financial years ending on 31 December 2023, 2024 and 2025.

It is resolved to appoint the independent firm ERNST & YOUNG, S.L. as Auditors of the Company for the 2023, 2024 and 2025 financial years, with tax identification number B-78970506 and registered office at C/ Raimundo Fernández Villaverde, 65, in Madrid (28003) with tax identification number B-78970506 and registered office at C/ Raimundo Fernández Villaverde, 65, in Madrid (28003), registered in the Mercantile Register of Madrid, Volume 9.364 general, 8.130 of section 3 of the Companies Book, Folio 68, Page no. 87.690-1, 1st entry, ROAC number S0530".

The minutes were unanimously approved.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró

Chairman of the Board of Directors